Enterprise Value
489.3M
Cash
138.5M
Avg Qtr Burn
-41.1M
Short % of Float
19.12%
Insider Ownership
0.51%
Institutional Own.
85.75%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Nexletol (bempedoic acid) Details Heterozygous familial hypercholesterolemia, Atherosclerotic cardiovascular disease , Hypercholesterolemia | Approved Quarterly sales | |
Nexlizet (bempedoic acid and ezetimibe) Details ASCVD (atherosclerotic cardiovascular disease) and HeFH (hypercholesterolemia) | Approved Quarterly sales | |
Nexletol (bempedoic acid) Details Heterozygous familial hypercholesterolemia, Atherosclerotic cardiovascular disease , Hypercholesterolemia, Cardiovascular risk reduction | sNDA Acceptance for review | |
Nexlizet (bempedoic acid and ezetimibe) Details Cardiovascular risk reduction | sNDA Acceptance for review |